These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.


They combined HFpEF and HFrEF

They used win ratios

Individual trials didn’t show mortality benefit but now there is?

https://pubmed.ncbi.nlm.nih.gov/35228754/